Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In this study, we investigated whether a patient’s germline TP53 codon 72 genotype, together with tumor p53 protein expression, was associated with the potential benefit of vitamin D supplementation in patients with digestive tract cancer who participated in the AMATERASU randomized clinical trial.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This study was conducted as a post hoc analysis of the AMATERASU trial, a randomized, double-blind, placebo-controlled trial investigating the effects of vitamin D supplementation in patients with digestive tract cancers, conducted at the International University of Health and Welfare Hospital in Japan.

Source: Methods.

This study was conducted as a post hoc analysis of the AMATERASU trial, a randomized, double-blind, placebo-controlled trial investigating the effects of vitamin D supplementation in patients with digestive tract cancers, conducted at the International University of Health and Welfare Hospital in Japan.

Source: Methods.

In the original trial, patients aged 30 to 90 years with cancers of the digestive tract (esophagus, stomach, small bowel, and colorectal), stages I to III, were recruited.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial

Secondary analysis · Cancers · 2026

Original publication title

Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial

Soichiro Fukuzato; Taisuke Akutsu; Hironori Ohdaira; Yutaka Suzuki; Mitsuyoshi Urashima

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Accumulating evidence suggests that vitamin D may influence cancer prognosis. We aimed to explore whether the TP53 codon 72 polymorphism (p.Pro72Arg; rs1042522) may be associated with differential effects of vitamin D supplementation on digestive tract cancer prognosis.

Methods:

This post hoc analysis of the AMATERASU randomized controlled trial included patients in whom both germline TP53 codon 72 genotype and p53 immunohistochemistry (IHC) assessment were available. Patients were stratified according to TP53 codon 72 genotype and p53 IHC expression. The association between vitamin D supplementation and relapse-free survival (RFS) was evaluated using Cox proportional hazards regression models within each subgroup.

Results:

A total of 333 participants (79.9%) out of 417 in the AMATERASU trial were included in the analysis. RFS was comparable between the vitamin D and placebo groups across the TP53 codon 72 genotype subgroups. The vitamin D group was significantly associated with more favorable RFS compared with the placebo group in patients with both the Arg/Arg genotype and high p53 IHC expression (HR, 0.32; 95% CI, 0.12 to 0.87; p = 0.03). However, with a fragility index of 2 and a non-significant three-way interaction among vitamin D supplementation, p53 IHC expression, and the Arg/Arg genotype (p for interaction = 0.09), these findings remain fragile despite reaching statistical significance, warranting careful interpretation.

Conclusions:

Vitamin D supplementation was associated with more favorable RFS among patients with digestive tract cancer who had both the Arg/Arg genotype and high p53 IHC expression. These exploratory findings warrant further investigation in prospective studies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Accumulating evidence suggests that vitamin D may influence cancer prognosis. We aimed to explore whether the TP53 codon 72 polymorphism (p.Pro72Arg; rs1042522) may be associated with differential effects of vitamin D supplementation on digestive tract cancer prognosis.

Source: Background

Abstract: Results

A total of 333 participants (79.9%) out of 417 in the AMATERASU trial were included in the analysis. RFS was comparable between the vitamin D and placebo groups across the TP53 codon 72 genotype subgroups. The vitamin D group was significantly associated with more favorable RFS compared with the placebo group in patients with both the Arg/Arg genotype and high p53 IHC expression (HR, 0.32; 95% CI, 0.12 to 0.87; p = 0.03). However, with a fragility index of 2 and a non-significant three-way interaction among vitamin D supplementation, p53 IHC expression, and the Arg/Arg genotype (p for interaction = 0.09), these findings remain fragile despite reaching statistical significance, warranting careful interpretation.

Source: Results

Abstract: Conclusions

Vitamin D supplementation was associated with more favorable RFS among patients with digestive tract cancer who had both the Arg/Arg genotype and high p53 IHC expression. These exploratory findings warrant further investigation in prospective studies.

Source: Conclusions
Authors’ abstract

Simple Summary

Vitamin D supplementation may reduce the risk of cancer recurrence, but the potential benefits may differ among patients with digestive tract cancer (esophagus, stomach, small bowel, and colorectal). Both patient-related genetic factors and tumor-related biological characteristics may help explain these differences. In this study, we investigated whether a patient’s germline TP53 codon 72 genotype, together with tumor p53 protein expression, was associated with the potential benefit of vitamin D supplementation in patients with digestive tract cancer who participated in the AMATERASU randomized clinical trial.

By examining these germline and tumor characteristics together, we aimed to identify patient and tumor profiles that are associated with a greater or smaller benefit from vitamin D supplementation. Our findings may provide new insights into how host genetic factors and tumor biology may jointly relate to the effectiveness of vitamin D and help generate hypotheses for future studies of personalized cancer treatment.

Abstract

Background:

Accumulating evidence suggests that vitamin D may influence cancer prognosis. We aimed to explore whether the TP53 codon 72 polymorphism (p.Pro72Arg; rs1042522) may be associated with differential effects of vitamin D supplementation on digestive tract cancer prognosis.

Methods:

This post hoc analysis of the AMATERASU randomized controlled trial included patients in whom both germline TP53 codon 72 genotype and p53 immunohistochemistry (IHC) assessment were available. Patients were stratified according to TP53 codon 72 genotype and p53 IHC expression. The association between vitamin D supplementation and relapse-free survival (RFS) was evaluated using Cox proportional hazards regression models within each subgroup.

Results:

A total of 333 participants (79.9%) out of 417 in the AMATERASU trial were included in the analysis. RFS was comparable between the vitamin D and placebo groups across the TP53 codon 72 genotype subgroups. The vitamin D group was significantly associated with more favorable RFS compared with the placebo group in patients with both the Arg/Arg genotype and high p53 IHC expression (HR, 0.32; 95% CI, 0.12 to 0.87; p = 0.03). However, with a fragility index of 2 and a non-significant three-way interaction among vitamin D supplementation, p53 IHC expression, and the Arg/Arg genotype (p for interaction = 0.09), these findings remain fragile despite reaching statistical significance, warranting careful interpretation.

Conclusions:

Vitamin D supplementation was associated with more favorable RFS among patients with digestive tract cancer who had both the Arg/Arg genotype and high p53 IHC expression. These exploratory findings warrant further investigation in prospective studies.

Publication and source details

Original title: Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial

Soichiro Fukuzato; Taisuke Akutsu; Hironori Ohdaira; Yutaka Suzuki; Mitsuyoshi Urashima

Cancers · 2026

* Correspondence: urashima@jikei.ac.jp; Tel.: +81-3-3433-1111© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Jikei University School of Medicinehttps://ror.org/039ygjf22 This research was funded by the Jikei University School of Medicine.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-07T19:41:42+00:00

DOI: 10.3390/cancers18203286 · PMC13702322